XML 50 R45.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business Combinations (Details Textual) (Cydex Pharmaceuticals, Inc [Member], USD $)
1 Months Ended 12 Months Ended
Jan. 31, 2011
company
licensee
medication
Dec. 31, 2012
employee_equivalent
Jan. 24, 2011
product
Business Acquisition [Line Items]      
Number of FDA-approved medications 5    
Number of licensees 3    
Minimum number of companies supported by CyDex for drug development efforts 40    
Cash paid to CyDex shareholders     $ 31,572,000
Percentage of related revenue   20.00%  
Amount exceeds to get related revenue for CyDex share holders   15,000,000  
Percentage of related revenue additional   10.00%  
Aggregate CyDex-related revenue   35,000,000  
Discount rate used to estimate future cash flows     21.50%
Number of employees required   5  
Investments for acquiring employees   1,500,000  
Business combination, weighted-average amortizaiton period intangible assets   20 years  
In-process research and development $ 3,200,000   $ 3,200,000
Number of acquirees in-process research and development products     2
Complete technology [Member]
     
Business Acquisition [Line Items]      
Discount rate used to estimate future cash flows     20.50%
Trademark and trade name [Member]
     
Business Acquisition [Line Items]      
Discount rate used to estimate future cash flows     20.50%